[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR100904165B1 - Dispersible acetaminophen tablet and manufacturing process thereof - Google Patents

Dispersible acetaminophen tablet and manufacturing process thereof Download PDF

Info

Publication number
KR100904165B1
KR100904165B1 KR1020070064866A KR20070064866A KR100904165B1 KR 100904165 B1 KR100904165 B1 KR 100904165B1 KR 1020070064866 A KR1020070064866 A KR 1020070064866A KR 20070064866 A KR20070064866 A KR 20070064866A KR 100904165 B1 KR100904165 B1 KR 100904165B1
Authority
KR
South Korea
Prior art keywords
acetaminophen
suspension
tablet
weight
children
Prior art date
Application number
KR1020070064866A
Other languages
Korean (ko)
Other versions
KR20090000923A (en
Inventor
안기영
길영식
정상영
하대철
안건석
신현모
박상만
박희찬
서영삼
송희용
이현민
양찬우
Original Assignee
한국유나이티드제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국유나이티드제약 주식회사 filed Critical 한국유나이티드제약 주식회사
Priority to KR1020070064866A priority Critical patent/KR100904165B1/en
Publication of KR20090000923A publication Critical patent/KR20090000923A/en
Application granted granted Critical
Publication of KR100904165B1 publication Critical patent/KR100904165B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 복용 및 보관이 용이한 어린이용 아세트아미노펜 현탁정 및 그의 제조방법에 관한 것으로, 어린이용 해열 및 진통제로 가장 많이 사용되는 아세트아미노펜을 기능성 당류를 이용하여 쓴맛을 개선하고 이를 현탁정으로 제조함으로써, 기존의 아세트아미노펜 어린이용 정제 또는 시럽보다 복용 편의성이 증진되고 보관이 용이한 제제를 제공한다.The present invention relates to an acetaminophen suspension tablet for children and a method for preparing the same, which are easy to take and store, and improve the bitter taste using functional sugars of acetaminophen, which is used most often as an antipyretic and analgesic agent for children, to prepare it as a suspension tablet. This provides a formulation that is easier to take and easier to store than conventional acetaminophen children's tablets or syrups.

아세트아미노펜, 현탁정, 파우더코팅, 고미 개선 Acetaminophen, suspension tablets, powder coating, improvement of taste

Description

아세트아미노펜 현탁정 및 그의 제조방법{Dispersible acetaminophen tablet and manufacturing process thereof}Acetaminophen suspension tablet and manufacturing method thereof

본 발명은 복용 및 보관이 용이한 어린이용 아세트아미노펜 현탁정 및 그의 제조방법에 관한 것으로서, 어린이용 해열 및 진통제로 가장 많이 사용되는 아세트아미노펜의 쓴 맛을 기능성 당류를 이용하여 개선하고 이를 적절한 붕해제를 첨가하여 현탁정으로 제조함으로써, 기존의 아세트아미노펜 어린이용 정제 또는 시럽보다 복용 편의성이 증진되고 보관이 용이한 제제를 제공하려고 한다.The present invention relates to an acetaminophen suspension tablet for children and a preparation method thereof, which is easy to take and store, and improves the bitter taste of acetaminophen, which is most used as an antipyretic and analgesic agent for children, by using functional sugars and appropriate disintegrating agent. By adding to prepare a suspension tablet, it is intended to provide a formulation that is easier to take and easier to store than conventional acetaminophen children's tablets or syrups.

아세트아미노펜(Acetaminophen)은 일명 파라세타몰(Paracetamol)로도 불리며, 성인은 물론 특히 어린이용 해열진통제로서 전세계적으로 가장 많이 사용되고 있는 약물이다. 대표적인 제품으로 얀센의 타이레놀(TYRENOL) 시리즈가 있으며, 정제로는 아세트아미노펜 함유 용량에 따라 80mg, 160mg, 325mg, 500mg 및 650mg 서방형 제제가 있으며, 어린이용 시럽도 있다. 특히 정제 복용 능력이 없는 유소아의 경우, 아세트아미노펜 정제는 분쇄하여 분말 형태로 복용하고 있고, 그 외에는 시럽으로 복용하고 있으며, 처방약뿐만 아니라 가정상비약으로도 많이 사용되고 있다. 그러나 아세트아미노펜은 맛의 특성상 고미가 매우 강하여 정제의 경우 적절한 기제로 제피한 고미가 차폐된 원료를 사용하여 제조되고 있다. 그러나 유·소아 환자의 경우는 정제를 분쇄하여 복용하기 때문에 분쇄과정을 통하여 고미차폐 작용이 소실되어 유·소아 환자가 복용하는데 있어 어려움이 있다. 또한 시럽의 경우, 감미제를 사용하여 고미를 경감시켰으나, 시럽의 특성상 보관 및 휴대성이 용이하지 않다.Acetaminophen, also known as paracetamol, is the most widely used drug worldwide as an antipyretic analgesic for adults as well as children. Representative products include Janssen's TYRENOL series. Tablets include 80mg, 160mg, 325mg, 500mg and 650mg sustained-release formulations, depending on the acetaminophen-containing dosage, and also children's syrup. In particular, infants who do not have the ability to take tablets, acetaminophen tablets are pulverized and taken in the form of powder, and other than that, they are taken as syrup, and are widely used as home medicines as well as prescription drugs. However, acetaminophen has a very strong taste due to the nature of the taste, and in the case of tablets, it is manufactured using a raw material shielded with a bitter gourd. However, in the case of infants and pediatric patients, the tablets are crushed and taken, and the chyme shielding effect is lost through the grinding process, which is difficult for the infants and pediatric patients to take. In addition, in the case of syrup, sweeteners were used to reduce bitterness, but the storage and portability of the syrup are not easy.

본 발명의 목적은 아세트아미노펜의 고미를 효과적으로 개선하여 복용편의성을 증진시키는 동시에 보관 및 휴대성이 용이한 아세트아미노펜 현탁정을 제공하는 것이다. SUMMARY OF THE INVENTION An object of the present invention is to provide an acetaminophen suspension tablet that is easily stored and portable at the same time, effectively improving the convenience of acetaminophen by enhancing the convenience of dosing.

본 발명의 아세트아미노펜 현탁정은 기능성 당류를 이용하여 아세트아미노펜의 고미가 효과적으로 개선되고, 동시에 적절한 붕해제를 첨가하여 신속하게 현탁되어 복용할 수 있는 이점이 있다. 그 결과로 유·소아 환자의 복약순응도 및 약물의 보관성이 획기적으로 향상되는 이점을 가진다. Acetaminophen suspension tablet of the present invention has the advantage that the taste of acetaminophen can be effectively improved by using functional sugars, and at the same time, it can be suspended and taken quickly by adding an appropriate disintegrant. As a result, the medication compliance and storage of drugs in infants and pediatric patients has the advantage that it is significantly improved.

본 발명의 적절한 실시형태에 따르면, 아세트아미노펜 함유 현탁정제 전체 중량에 대하여 아세트아미노펜 46~58.5중량%, 기능성 당류 10.2~18중량%, 붕해제 31~35중량%, 그리고 활택제 0.3~1.0중량%를 포함하는 아세트아미노펜 함유 현탁정제 조성물이 제공될 수 있다.According to a preferred embodiment of the present invention, 46 to 58.5 weight percent of acetaminophen, 10.2 to 18 weight percent of functional sugars, 31 to 35 weight percent of disintegrant, and 0.3 to 1.0 weight percent of lubricant, based on the total weight of acetaminophen-containing suspension tablet An acetaminophen containing suspension tablet composition may be provided.

본 발명의 다른 적절한 실시 형태에 따르면, 기능성 당류는 수크랄로스인 것이 바람직하다. According to another suitable embodiment of the present invention, the functional saccharide is preferably sucralose.

본 발명의 또 다른 적절한 실시 형태에 따르면, 붕해제는 F-MELT 인 것이 바람직하다. According to another suitable embodiment of the invention, the disintegrant is preferably F-MELT.

본 발명의 또 다른 적절한 실시 형태에 따르면, 아세트아미노펜의 함량은 정제당 80mg 또는 160mg이 된다. According to another suitable embodiment of the present invention, the content of acetaminophen is 80 mg or 160 mg per tablet.

이하, 본 발명을 상세하게 설명한다. EMBODIMENT OF THE INVENTION Hereinafter, this invention is demonstrated in detail.

본 발명의 아세트아미노펜 현탁정 제제는 아세트아미노펜, 아세트아미노펜의 고미 개선을 위한 기능성 당류로서 수크랄로스(Sucralose), 신속한 현탁 과정을 달성하기 위한 붕해제로서 F-MELT, 그리고 활택제를 혼합하여 정제화하는 매우 간편한 공정을 통하여 제조된다.The acetaminophen suspension tablet formulations of the present invention are highly purified by mixing acetaminophen, sucralose as a functional saccharide for improving the taste of acetaminophen, F-MELT as a disintegrant to achieve a rapid suspension process, and glidants. Manufactured through a simple process.

본 발명의 아세트아미노펜 현탁정 제제는 제제 전체 중량 대비 아세트아미노펜 46~58.5중량%, 수크랄로오스 10.2~18중량%, F-MELT 31~35중량%, 그리고 활택제 0.3~1.0중량%로 이루어진다. The acetaminophen suspension tablet formulation of the present invention is composed of 46-58.5 wt% of acetaminophen, 10.2-18 wt% of sucralose, 31-35 wt% of F-MELT, and 0.3-1.0 wt% of a lubricant, based on the total weight of the preparation. .

상기 고미 개선제로 사용되는 수크랄로스(삼양제넥스(주) 제조, 한국)는 설탕에 비해 약 400배의 감미를 가지면서도 인체에는 전혀 무해한 감미제로서, 유·소아 환자에게 고미 개선과 함께 인체에도 안전한 제제를 제공할 수 있게 한다. 본 발명은 또한 고미 개선제와 함께 향미제를 사용할 수 있다. 향미제는 고미 개선제의 함량 범위 내에서 조절할 수 있다. Sucralose (Samyang Genex Co., Ltd., Korea) used as a bitter improver is a sweetener that is about 400 times sweeter than sugar and is completely harmless to the human body. Enable to provide The present invention may also use flavoring agents in conjunction with bitter improvers. The flavourant can be adjusted within the content range of the flavourant.

또한, 붕해제로 사용되는 F-MELT(후지케미컬 제조, 일본)는 물에서 정제의 신속한 붕해를 달성시켜 신속한 현탁액을 조제할 수 있게 하는 동시에, 정제의 제 정성 또한 매우 우수하여 품질이 우수한 아세트아미노펜 현탁정제를 제공할 수 있게 한다. F-MELT는 D-만니톨, 자일리톨, 미결정셀룰로오스, 크로스포비돈(crospovidone), 제2인산칼슘(Calcium Phosphate, Dibasic)으로 이루어진 부형제로, 본 발명의 경우는 하기 표 1의 조성을 가지는 F-MELT Type C가 바람직하게 사용될 수 있다. In addition, F-MELT (Fuji Chemical Co., Japan) used as a disintegrant can achieve rapid disintegration of tablets in water to prepare a rapid suspension, and at the same time, the tablet formulation is also very excellent in quality acetaminophen. Allow to provide suspension tablets. F-MELT is an excipient consisting of D-mannitol, xylitol, microcrystalline cellulose, crospovidone, dicalcium phosphate (Calcium Phosphate, Dibasic), and in the case of the present invention, F-MELT Type C Can be preferably used.

[표 1] F-MELT Type C의 조성[Table 1] Composition of F-MELT Type C

조성Furtherance 범위range 수재 약전명Pharmacopoeia D-만니톨D-mannitol 50 - 66 % 50-66% USP-NF / EP / JPUSP-NF / EP / JP 자일리톨Xylitol 2 - 10 %2-10% USP-NF / EP / JPUSP-NF / EP / JP 미결정셀룰로오스Microcrystalline cellulose 10 - 20 %10-20% USP-NF / EP / JPUSP-NF / EP / JP CrospovidoneCrospovidone 5 - 9 %5-9% USP-NF / EP / JPUSP-NF / EP / JP Calcium Phosphate, DibasicCalcium Phosphate, Dibasic 2 - 9 %2-9% USP-NF / EP / JPUSP-NF / EP / JP

이하에서는 본 발명을 하기의 실시예에 의하여 설명된다. 그러나 본 발명이 이들 실시 예에 한정되는 것은 아니다.In the following the invention is illustrated by the following examples. However, the present invention is not limited to these examples.

실시 예 Example

실시 예1Example 1

아세트아미노펜 80mg 현탁정의 제조 Preparation of Acetaminophen 80mg Suspension Tablet

아세트아미노펜 800g에 수크랄로스 200g, F-MELT 590g, 스트로베리미크론 100g 및 스테아린산마그네슘 10g을 첨가하여 균일하게 혼합한 후, 1정당 170mg의 질량으로 타정하여 아세트아미노펜 80mg 함유 현탁정을 제조하였다. To 800 g of acetaminophen, 200 g of sucralose, 590 g of F-MELT, 100 g of strawberry micron and 10 g of magnesium stearate were added and mixed uniformly, followed by tableting at a mass of 170 mg per tablet to prepare a suspension tablet containing acetaminophen 80 mg.

원료명Raw material name 정제당 사용량(mg)Usage per tablet (mg) 중량%weight% 아세트아미노펜Acetaminophen 80.080.0 47.0647.06 수크랄로스Sucralose 20.020.0 11.7611.76 F-MELTF-MELT 59.059.0 34.7134.71 스트로베리미크론Strawberry Micron 10.010.0 5.885.88 스테아린산마그네슘Magnesium stearate 1.01.0 0.590.59 system 170.0170.0 100.00100.00

실시 예2Example 2

아세트아미노펜 160mg 현탁정의 제조 Preparation of Acetaminophen 160mg Suspension Tablet

아세트아미노펜 1600g에 수크랄로스 300g, F-MELT 890g 및 스테아린산마그네슘 10g을 균일하게 혼합한 후, 1정당 280mg의 질량으로 타정하여 아세트아미노펜 160mg 함유 현탁정을 제조하였다. Sucrose 300g, F-MELT 890g, and magnesium stearate 10g were uniformly mixed with 1600g of acetaminophen, and then, tableted at a mass of 280mg per tablet to prepare 160mg of acetaminophen.

원료명Raw material name 정제당 사용량(mg)Usage per tablet (mg) 중량%weight% 아세트아미노펜Acetaminophen 160.0160.0 57.1457.14 수크랄로스Sucralose 30.030.0 10.7110.71 F-MELTF-MELT 89.089.0 31.7931.79 스테아린산마그네슘Magnesium stearate 1.01.0 0.360.36 system 280.0280.0 100.00100.00

비교 예1Comparative Example 1

아세트아미노펜 80mg 일반정제Acetaminophen 80mg Regular Tablet

아세트아미노펜 800g에 직타 유당 500g, 미결정셀룰로오스 3400g, 전분글리콜산나트륨 50g 및 스테아린산마그네슘 10g을 균일하게 혼합한 후, 1정당 170mg의 질량으로 타정하여 아세트아미노펜 80mg 함유 일반정을 제조하였다. 500 g of acetaminophen was uniformly mixed with 500 g of straight sugar lactose, 3400 g of microcrystalline cellulose, 50 g of sodium starch glycolate, and 10 g of magnesium stearate, followed by compression to a mass of 170 mg per tablet to prepare 80 mg of acetaminophen.

원료명Raw material name 정제당 사용량(mg)Usage per tablet (mg) 중량%weight% 아세트아미노펜Acetaminophen 80.080.0 47.0647.06 직타유당Direct lactose 50.050.0 29.4129.41 미결정셀룰로오스Microcrystalline cellulose 34.034.0 20.0020.00 전분글리콜산나트륨Sodium starch glycolate 5.05.0 2.942.94 스테아린산마그네슘Magnesium stearate 1.001.00 0.590.59 system 170.0170.0 100.00100.00

비교 예2Comparative Example 2

어린이용 타이레놀정 80mg(한국얀센(주)) Tylenol Tablets for Children 80mg (Jansen Co., Ltd.)

비교 예3Comparative Example 3

타이레놀정 160mg(한국얀센(주))Tylenol tablets 160mg (Korea Janssen Co., Ltd.)

본 발명에 따라 제조된 아세트아미노펜 현탁정의 고미 개선 효과 및 붕해 성능을 하기와 같이 평가하였다. 그 결과를 표1 및 표2에 나타내었다.Taste improvement and disintegration performance of acetaminophen suspension tablets prepared according to the present invention were evaluated as follows. The results are shown in Table 1 and Table 2.

실험 예1Experimental Example 1

아세트아미노펜 현탁정의 현탁화의 신속성 정도를 측정하기 위하여 어린이용 약 스푼의 용량인 5ml의 정제수에서 현탁 시험을 실시하였다.In order to measure the degree of rapidity of suspension of acetaminophen suspension tablets, suspension tests were performed in 5 ml of purified water, the capacity of about a tablespoon for children.

시험 제제Test formulation 현탁 시간 (5ml 정제수내 완전 붕해 시간)Suspension time (complete disintegration time in 5ml purified water) 실시 예1 현탁정Example 1 Suspension Tablet 20초20 seconds 실시 예2 현탁정Example 2 Suspension Tablet 23초23 seconds

본 발명의 실시 예에 따른 아세트아미노펜 제제는 매우 신속하게 붕해되며 현탁되었다. Acetaminophen formulations according to embodiments of the invention disintegrate and suspend very quickly.

실험 예2Experimental Example 2

아세트아미노펜 현탁정의 고미 개선 효과를 확인하기 위하여 어린이용 약 스푼의 1회 용량인 5ml의 정제수에 실시 예1 및 2를 현탁하고, 비교 예1 - 3의 정제는 분쇄하여 정제수 5ml에 현탁하여 그 맛을 비교해 보았다.Examples 1 and 2 were suspended in 5 ml of purified water, which is a one-time dose of a children's spoon, to confirm the improvement of acetic aminophene suspension tablets. Compared.

시험예Test Example 쓴맛의 정도Bitterness 매우 쓰다Very write 쓰다write 조금 쓰다Write a little 거의 쓰지 않다Rarely used 쓰지 않다Write 실시 예1 현탁액Example 1 Suspension OO 실시 예2 현탁액Example 2 Suspension OO 비교 예1 분쇄물 현탁액Comparative Example 1 Grind Suspension OO 비교 예2 분쇄물 현탁액Comparative Example 2 Grind Suspension OO 비교 예3 분쇄물 현탁액Comparative Example 3 Grind Suspension OO

그 결과, 본 발명의 아세트아미노펜 현탁정의 고미 개선 효과가 매우 우수하였다. As a result, the taste improvement effect of the acetaminophen suspension tablet of this invention was very excellent.

본 발명에 의하면, 어린이용 해열 및 진통제로 가장 많이 사용되는 아세트아미노펜의 쓴 맛을 기능성 당류를 이용하여 개선하고 이를 적절한 붕해제를 첨가하여 현탁정으로 제조함으로써, 기존의 아세트아미노펜 어린이용 정제 또는 시럽보다 복용 편의성이 증진되고 보관이 용이한 제제를 제공할 수 있다.According to the present invention, by improving the bitter taste of acetaminophen, which is most often used as an antipyretic and analgesic for children by using functional sugars, and preparing it as a suspension tablet by adding a suitable disintegrant, the existing acetaminophen children's tablet or syrup It is possible to provide formulations which are more convenient to take and which are easier to store.

Claims (4)

아세트아미노펜함유 현탁정제 전체 중량에 대하여 아세트아미노펜 46~58.5중량%, 수크랄로스 10.2~12중량%, 붕해제 31~35중량%, 그리고 활택제 0.3~0.6중량%를 포함하고,46 to 58.5 weight percent of acetaminophen, 10.2 to 12 weight percent of sucralose, 31 to 35 weight percent of disintegrant, and 0.3 to 0.6 weight percent of lubricant, based on the total weight of acetaminophen-containing suspension tablet, 상기 붕해제는 붕해제 전체 중량 대비 D-만니톨 50~66중량%, 자일리톨 2 내지 10중량%, 미결정셀룰로오스 10 내지 20중량%, 크로스포비돈 5 내지 9 중량% 및 제2인산칼슘 2 내지 9중량%를 포함하는 조성물인 것을 특징으로 하는 아세트아미노펜 함유 현탁정제 조성물The disintegrant is 50 to 66% by weight of D-mannitol, 2 to 10% by weight of xylitol, 10 to 20% by weight of microcrystalline cellulose, 5 to 9% by weight of crospovidone and 2 to 9% by weight of dicalcium phosphate Acetaminophen-containing suspension tablet composition, characterized in that the composition comprising a 삭제delete 삭제delete 청구항 1에 있어서, 상기 아세트아미노펜의 함량은 정제당 80mg 또는 160mg인 것을 특징으로 하는 아세트아미노펜 함유 현탁정제 조성물.The acetaminophen-containing suspension tablet composition according to claim 1, wherein the content of acetaminophen is 80 mg or 160 mg per tablet.
KR1020070064866A 2007-06-29 2007-06-29 Dispersible acetaminophen tablet and manufacturing process thereof KR100904165B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020070064866A KR100904165B1 (en) 2007-06-29 2007-06-29 Dispersible acetaminophen tablet and manufacturing process thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020070064866A KR100904165B1 (en) 2007-06-29 2007-06-29 Dispersible acetaminophen tablet and manufacturing process thereof

Publications (2)

Publication Number Publication Date
KR20090000923A KR20090000923A (en) 2009-01-08
KR100904165B1 true KR100904165B1 (en) 2009-06-22

Family

ID=40484051

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020070064866A KR100904165B1 (en) 2007-06-29 2007-06-29 Dispersible acetaminophen tablet and manufacturing process thereof

Country Status (1)

Country Link
KR (1) KR100904165B1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010006835A (en) * 1999-03-25 2001-01-26 김선진 Rapidly disintegrable tablet for oral administration
KR20050001738A (en) * 2003-06-26 2005-01-07 주식회사 트윈클리틀스타 Method and system for providing geographical information using subdomain in internet map

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010006835A (en) * 1999-03-25 2001-01-26 김선진 Rapidly disintegrable tablet for oral administration
KR20050001738A (en) * 2003-06-26 2005-01-07 주식회사 트윈클리틀스타 Method and system for providing geographical information using subdomain in internet map

Also Published As

Publication number Publication date
KR20090000923A (en) 2009-01-08

Similar Documents

Publication Publication Date Title
JP4989733B2 (en) Orally disintegrating tablets
WO2000057857A1 (en) Rapidly disintegrable tablet for oral administration
JP5215172B2 (en) Dry type quick-disintegrating tablet
CN108272765B (en) Pharmaceutical composition containing vardenafil hydrochloride, orally disintegrating tablet, and preparation and application thereof
Mohapatra et al. Formulation, development and evaluation of patient friendly dosage forms of metformin, Part-I: Orally disintegrating tablets
US7993673B2 (en) Swallow tablet comprising paracetamol
Patel et al. Development and invitro evaluation of fast dissolving tablets of glipizide
JP2003034655A (en) Fast degradable solid tablet
US20160331710A1 (en) Effervescent compositions containing n-acetylcysteine
PT1807156T (en) New pharmaceutical formulations useful in the treatment of insomnia
KR100904165B1 (en) Dispersible acetaminophen tablet and manufacturing process thereof
KR101046789B1 (en) Amlodipine quick disintegrating tablet with improved stability and preparation method thereof
JP2003081821A (en) Medicinal composition
Kadam et al. Formulation and Evaluation of Orodispersible Tablets of Levamisole Hydrochloride
KR20040091135A (en) Tablet containing pilsicainide hydrochloride(dry)
Patil et al. Preparation and Evaluation of Fast Dissolving Tablet Tramadol Hydrochloride
JP2005289906A (en) Medicinal composition
Durghe et al. Formulation Development and Characterization of Anti-Retroviral Agents
Sastry et al. Formulation and Evaluation of Orodispersible Tablets of an Antiulcer Agent
Kolli et al. Formulation and evaluation of matrix tablet of ramipril
Pandey et al. Formulation of Oro-Dispersible Tablets Of Faxofenadine Hydrochloride And Its Evaluation.
JP2005289905A (en) Medicinal composition
Pimple et al. FORMULATION AND EVALUATION OF MOUTH DISSOLVING TABLETS OF MONTELUKAST SODIUM” MONTELUKAST SODIUM
Soni et al. Formulation and Evaluation of Oro-dispersible Tablets of Ondansetron Hydrochloride by Direct Compression Method.
JP2005289902A (en) Medicinal composition

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130905

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20140516

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20150712

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20160524

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20180523

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20190411

Year of fee payment: 11